https://www.selleckchem.com/pr....oducts/pclx-001-ddd8
Sickle cell disease (SCD) patients are commonly affected by pulmonary complications such as acute chest syndrome (ACS), pulmonary embolism (PE) and pneumonia that contribute to significant mortality risks. With a greater susceptibility to infection, they are deemed to be vulnerable patients during the current COVID-19 pandemic. In emerging small case studies of SCD patients with COVID-19 and further complicated by pneumonia, ACS, and/or PE, the clinical benefits of early exchange transfusion and Tocilizumab are evident. Howeve
إعجاب
علق
شارك
